Shield Therapeutics plc (LON:STX – Get Free Report)’s share price passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 3.19 ($0.04) and traded as low as GBX 2.63 ($0.03). Shield Therapeutics shares last traded at GBX 2.80 ($0.04), with a volume of 2,737,460 shares trading hands.
Shield Therapeutics Stock Performance
The stock has a market cap of £26.35 million, a P/E ratio of -0.69 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16. The stock has a 50-day simple moving average of GBX 3.19 and a 200-day simple moving average of GBX 3.16.
Insider Activity at Shield Therapeutics
In other news, insider Anders Lundstrom acquired 575,000 shares of Shield Therapeutics stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of GBX 4 ($0.05) per share, for a total transaction of £23,000 ($29,854.62). 62.16% of the stock is currently owned by insiders.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- Joby Aviation: Operational Momentum vs. Market Sentiment
- Stock Sentiment Analysis: How it Works
- Broadcom’s Big Outperformance Shows Strength Amid Tariff Decline
- There Are Different Types of Stock To Invest In
- Carvana: Can Turnaround Strength Outdrive Market Headwinds?
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.